April 2013, Vol 2, No 2
Information Overload – the Search for Clinical Relevance in the Oncology LiteratureUncategorized
The field of oncology is changing at an unprecedented rate. Not that long ago, a few dozen chemotherapeutic agents were used to treat a wide variety of tumor types – and most of them were used empirically. It used to be relatively easy to keep current on advances as only a handful of randomized trials were published or presented each year for the most common disease sites. Now, there are well over 100 commercially available anticancer agents, many of which have targeted applications, and it seems that new FDA-approved indications are being announced on a weekly basis. Every day, oncologists are inundated with information touting the results of the latest randomized trials for both common and uncommon malignancies. Even for an academic oncologist, it is challenging to keep current on the constant flow of new data.
It can be even more challenging to determine which results actually represent clinically meaningful advances. Many of the recent advances in oncology are truly remarkable scientific achievements, and we remain hopeful that they will translate into greater clinical gains. However, trials with statistically significant results that are of marginal clinical benefit do not justify the empiric use of expensive, state-of-the-art treatments in all patients with an advanced, incurable disease. This approach is neither scientifically rational nor economically sustainable. What such studies tell us is that some patients do benefit from newer targeted therapies. It is now incumbent upon us to take these findings a step further by defining the predictive factors that will prospectively identify those patients who will benefit so we can begin to direct our treatments in a more rational, effective, and fiscally sound manner.
That is why Personalized Medicine in Oncology exists. We offer articles, interviews, and news exploring the best ways to effectively personalize oncology treatments. And now, we want your feedback. Please visit and bookmark us at www.personalizedmedonc.com to weigh in on the topics presented in our pages and on our Web site. We are looking forward to hearing from you and maintaining a meaningful dialogue.
Al B. Benson III, MD
PMO Editor in Chief
The health reform that Mitt Romney passed in 2006 in Massachusetts presaged President Obama’s, and its results are showing what we can expect nationwide. The latest warning comes in a huge new tax increase proposed by Governor Deval Patrick. The second-term Democrat followed his party’s recent habit and proposed an [ Read More ]
The Affordable Care Act and Oncology Personalized Medicine: Compatibility and the Governing Dynamics of Healthcare
Our last column examined the tripartite nature of healthcare: a clinical/business/policy entity with each of the 3 sectors influencing the net condition of healthcare. While the healthcare entity should act in balance, in reality each sector periodically springs forward with powerful initiatives and “takes charge” of healthcare until another sector [ Read More ]